Pfizer Posts Third-Quarter 2026 Results, Lifts Full-Year Revenue Outlook

what happened

Pfizer released its third-quarter 2026 report, showing revenue of $16.6 billion, roughly unchanged from a year earlier. Excluding Comirnaty and Paxlovid, sales rose 7% on an operational basis, while launched and acquired products climbed 32%. Adjusted diluted EPS came in at $0.87 and reported EPS at $0.56, TradingView reports.

The company now expects 2026 revenue of $62.0 to $64.0 billion, with the midpoint lifted by $1.5 billion from the earlier $60.5 to $62.5 billion range. Adjusted EPS guidance was narrowed to $2.95 to $3.05 from $2.80 to $3.00. The outlook includes a one-time $650 million charge tied to the Innovent Biologics in-licensing agreement, worth about $0.10 per share.

Growth came mainly from Eliquis, Padcev, Vyndaqel, Nurtec and Lorbrena, partly offsetting weaker COVID-19 products and Prevnar. Through nine months Pfizer paid $7.3 billion in dividends, and no buybacks had been completed in 2026.

why it matters

For markets, the upward revision rests on newer medicines, while the drop in COVID product sales has been absorbed. The Innovent charge weighs on reported profit but is already built into the revised outlook. Investors will watch how well launched products can replace pandemic-related revenue.

market impact

Pfizer shares: raised revenue and profit outlook supports the stock

• ▲Pfizer shares pressure up — raised revenue and profit outlook supports the stock

tags

instruments